Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872831 | 0.92 | ADRB2 (0.54) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL4866776 | 0.88 | ADRB2 (0.53) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL7724551 | 0.81 | ADRB2 (0.48) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| Hydrochloric Acid SCHEMBL11692252 | 0.80 | ADRB2 (0.48) | ADRB2ADRB1ADRB3LMNAALDH1A1 | |
| SCHEMBL9767993 | 0.80 | ADRA2A (0.68) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL1461292 | 0.80 | ADRA2A (0.68) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL29278698 | 0.79 | ADRA2A (0.66) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL11692156 | 0.76 | ADRB1 (0.57) | ADRB2ADRB1ADRA1DDRD2 | |
| SCHEMBL965291 | 0.76 | ADRB1 (0.47) | ADRB2ADRB1ADRB3 | |
| SCHEMBL4122825 | 0.76 | ADRB2 (0.50) | ADRB2ADRA2AADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7105701-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060183918-A1 | Beta 2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-08-17 | — | — | US | disclosed |
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-11-24 | — | — | US | disclosed |
| US-20050209275-A1 | Beta 2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-22 | — | — | US | disclosed |
| US-6919482-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040186080-A1 | Beta 2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-09-23 | — | — | US | disclosed |
| US-6713651-B1 | RESPIRATORY AND NERVOUS SYSTEM DISORDERS, PREMATURE LABOR | THERAVANCE, INC. | 2004-03-30 | — | — | US | disclosed |
| US-6541669-B1 | Multibinding amine compounds which are beta 2 adrenergic receptor agonists useful in treatment and prevention of respiratory diseases such as asthma, bronchitis | THERAVANCE, INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1235787-A1 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001042193-A1 | β2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186080-A1 | Beta 2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRA2A 5/4885ADRA2B 3/4885 |
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRA2A 5/4885ADRA2B 3/4885 |
| US-20050209275-A1 | Beta 2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRA2A 5/4885ADRA2B 3/4885 |
| US-20060183918-A1 | Beta 2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRA2A 5/4885ADRA2B 3/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRA2A 5/4885ADRA2B 3/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRA2A 5/4885ADRA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.